Analyst firms · Piper Sandler · DXCM
Piper Sandler DXCM price target and rating history
DexCom Inc. (DXCM) · Health Care
Piper Sandler rates DexCom Inc. (DXCM) Overweight with a $750 price target, as of its latest action on Nov 3, 2021. It has published 3 rating actions on DXCM since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a DXCM price target in the last 12 months, the median target is $86.
- Current rating
- Overweight
- Price target
- $750
- Median target, all firms
- $86
- Actions on DXCM
- 3
Piper Sandler price target on DXCM
Every Piper Sandler rating on DXCM
- Nov 3, 2021
- Sep 16, 2021
- Jul 30, 2021
How other firms rate DXCM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $115 | Oct 7, 2026 |
| Deutsche Bank | Buy | $86 | Jun 23, 2026 |
| The Benchmark Company | Buy | $77 | May 12, 2026 |
| Evercore ISI | Outperform | $90 | Mar 24, 2026 |
| Morgan Stanley | Overweight | $75 | Dec 2, 2025 |
Questions about Piper Sandler and DXCM
- What is Piper Sandler's price target for DXCM?
- Piper Sandler's latest stated price target for DexCom Inc. (DXCM) is $750, from its action on Nov 3, 2021.
- What is Piper Sandler's rating on DXCM?
- Piper Sandler rates DXCM Overweight, a bullish rating, as of Nov 3, 2021.
- When did Piper Sandler last change its view on DXCM?
- On Nov 3, 2021, Piper Sandler raises its price target to $750 from $675, keeps Overweight.
- How does Piper Sandler's DXCM target compare with other analysts?
- Across 5 firms with a DXCM price target in the last 12 months, the median target is $86.
More DXCM rating histories
All Piper Sandler ratingsDXCM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.